Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Potential Biomarkers Found for Early Alzheimer's Diagnosis

By LabMedica International staff writers
Posted on 05 Nov 2013
The presymptomatic stage of Alzheimer’s disease (AD) occurs at least one decade before the clinical onset, highlighting the need for validated biomarkers that reflect this early period.

The success of future intervention strategies for AD will likely rely on the development of treatments, once a definitive diagnosis has been made early in the course of the disease, before irreversible brain damage occurs.

Scientists at Linköping University (Sweden) working with international collaborators, performed a targeted search for lysosomal network proteins in human cerebrospinal fluid (CSF). More...
They studied samples of spinal marrow from 20 Alzheimer's patients and an equal number of healthy control subjects. The screening was aimed at 35 proteins that are associated with the lysosomal network.

CSF levels of the core AD biomarkers, including Aβ1–42, T-tau and P-tau181P phosphorylated at threonine181, were determined using INNOTEST enzyme linked immunosorbent assay (ELISA) kits (Innogenetics; Ghent, Belgium). Albumin levels were measured by immunonephelometry on a Beckman Image Immunochemistry system (Beckman Instruments, Beckman Coulter; Brea, CA, USA). Western blots were performed on CSF samples and immunodetection of the bound antibodies was performed using Amersham ECL detection systems (GE Healthcare; Pittsburgh, PA, USA).

Of thirty-four candidate lysosomal network proteins, they found that only six proteins were increased, indicating that a specific subset of lysosomal network proteins is overexpressed in the CSF of AD patients. The scientists identified the six as the endosomal proteins rat sarcoma (ras) in the brain 3, (Rab3) andRab7; the early endosomal antigen 1 (EEA1); the lysosomal-associated membrane proteins 1 and 2 (LAMP-1, LAMP-2), and the autophagy microtubule-associated protein 1 light chain 3 (LC3) and all were significantly upregulated in the CSF of AD patients.

Katarina Kågedal, PhD, the lead author of the study said, “In victims of Alzheimer's, something happens to the lysosomes so that they can't manage to take care of the surplus of beta amyloid. They fill up with junk that normally is broken down into its component parts and recycled.” Her hope is that the group's discovery will contribute to early diagnoses of the illness, which is necessary in the first stage in order to be able to begin reliable clinical tests of candidates for drugs, but perhaps the six lysosomal proteins could also be targets for developing drugs. The study was published on October 8, 2013, in the journal Neuromolecular Medicine.

Related Links:

Linköping University
Innogenetics
Beckman Instruments 
 



Gold Member
Respiratory Syncytial Virus Test
OSOM® RSV Test
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Capillary Blood Collection Tube
IMPROMINI M3
Gel Cards
DG Gel Cards
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.